National Institutes of Health Antibody Interest Group
Search  
NIH Antibody Interest Group 
 
Antibody Interest Group

The NIH Antibody Interest Group (ABIG) aims to promote information exchange and interaction among NIH scientists who work on various aspects of antibody engineering and therapy.  The success of antibody therapy requires a deep understanding of biological systems in relation to molecular and cell biology, immunology, biochemistry, and microbiology as well as diseases such as cancer, autoimmunity, and infectious diseases. Interest in antibody therapy crosses traditional biomedical disciplinary boundaries. ABIG provides an open forum for multidisciplinary discussion among colleagues who otherwise may have limited contact. The principal ABIG activities are monthly meetings on current topics. The monthly ABIG meetings are open to everyone interested. These meetings are devoted to research seminars on numerous aspects of antibody engineering and therapy that will be presented by both NIH scientists and outside speakers.

A Steering Committee comprised of NIH scientists from basic and clinical disciplines is responsible for running the ABIG. Their principal job is to select speakers for the monthly meetings. The committee consists of:

Chair: Mitchell Ho (homi@mail.nih.gov)
Dimiter Dimitrov (Dimiter.dimitrov@nih.gov)
Raffit Hassan (hassanr@mail.nih.gov)
Rimas Orentas (orentasrj@mail.nih.gov)

 

Seminars in 2014

Raffit Hassan (NCI)
January 24, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Mesothelin targeted cancer therapies in clinical trials"

 

Robert Kreitman (NCI)
February 28, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Recombinant immunotoxins induce complete response in hematologic malignancies"

 

Peter Kwong (NIAID)
March 28, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
“Antibodies as vaccine templates for RSV and HIV-1”

 

Adrienne H. Long (NCI)
April 11, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
“Rapid Exhaustion in Human T Cells Induced by Chimeric Antigen Receptor Ectodomain Interactions”

 

Eric Sundberg (University of Maryland School of Medicine)
May 23, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Antibody-mediated Fc receptor effector functions: Protein structure and engineering approaches to developing novel therapeutics"

 

Michael B. Atkins (Georgetown University)
September 26, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Update on cancer immunotherapy with immune checkpoint inhibitors"

 

Changshou Gao (MedImmune, Inc.)
October 24, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
TBA

 

Sridhar Ramaswamy (Harvard University)
November 14, 2014 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
“Antibody-based targeting of dormant cancer cells”

 

Seminars in 2013

David FitzGerald (NCI)
January 25, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Immunotoxin development for cancer treatment – future directions"

 

Mitchell Ho (NCI)
February 22, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Novel monoclonal antibodies targeting glypican-3 in liver cancer" (sponsored by NCI/CCR)

Roy A. Mariuzza (University of Maryland, College Park)
March 22, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Variable Lymphocyte Receptors from Fish: Nature's Other Solution to Highly Specific Antigen Recognition"

Louis M. Weiner (Georgetown University)
April 26, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Antibody-Targeted Cancer Immunotherapy”

Rimas Orentas (NCI)
May 24, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Targeting Pediatric Malignancies with Chimeric Antigen Receptors (CARs)”

Ronit Mazor (NCI)
September 27, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Immunotoxins with Low Immunogenicity by Identifying and Removing T Cell Epitopes”

Wendy Weinberg (FDA)
October 25, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"The Promise and Challenge of Therapeutic Antibodies in Oncology: A Regulatory Perspective”

Seminars in 2012

Adrian Wiestner (NHLBI)
January 27, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Targeting CD20 in Chronic Lymphocytic Leukemia: ADCC, Complement, and Pharmakokinetics"

 

Hisataka Kobayashi (NCI)
February 24, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Photo-immunotherapy; a new highly selective cancer therapy with armed antibody based on photo-physics and chemistry"

 

Sarah K. Browne (NIAID)
March 23, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Immunodeficiency due to anti-IFN-γ autoantibodies: the roles of titer and avidity in determining biological function"

 

Weizao Chen (NCI Frederick National Lab)
April 27, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Engineered single antibody domains (eAds) and eAd-based multispecific fusion proteins as candidate therapeutics"

 

Viktor Roschke (Zyngenia, Inc.)
May 25, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"
Zybodies: multi-specific, multi-valent single-protein therapeutics"

 

Brad St. Croix (NCI Frederick National Lab)
June 22, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Development of Therapeutic Antibodies that Discriminate Pathological and Physiological Angiogenesis"

 

James N. Kochenderfer (NCI)
September 28, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Treatment of B-cell Malignancies with T cells Expressing Anti-CD19 Chimeric Antigen Receptors"

 

Charles B. Shoemaker (Tufts University)
December 14, 2012 (Friday) 10:00-11:00 a.m., Bldg. 33 Room 1N09, NIAID, Bethesda
"A general platform for rapid development of simple recombinant antitoxin products" (sponsored by NIAID)

 

Seminars in 2011

Peter D. Kwong (NIAID)
January 28, 2011 (Friday) 10-11 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Identification, characterization, and elicitation of broadly neutralizing antibodies that target the CD4-binding site of HIV-1" 

Christopher C. Broder (Uniformed Services University)

February 25, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"A Cross-Reactive Human Monoclonal Antibody Therapeutic for Hendra Virus and Nipah Virus"

Ira Pastan (NCI)
March 25, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Recombinant Immunotoxin Treatment of Cancer"

 

Seth Pincus (The Research Institute for Children, New Orleans)

April 21, 2011 (Thursday) 12:30-1:30 p.m., Bldg. 37 5th Floor Conference Room, NCI, Bethesda

“Quantitative confocal microscopy defines mechanisms of intracellular neutralization of protein toxins by antibody”

Debbie Hodge (NCI)
April 22, 2011 (Friday) 10:15-11:15 a.m., Bldg. 549 Executive Board Room, NCI, Frederick

“Chronic Interferon-gamma expression - impact on B cells and autoimmunity”

Martin F Flajnik (University of Maryland School of Medicine)
May 27, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"The emergence and evolution of single-domain V regions"

Syd Johnson (MacroGenics, Inc.)
September 23, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Optimized bispecific antibody fragments for oncology and autoimmunity"

Seminars in 2010

 

Christoph Rader (NCI)
May 5, 2010 (Friday) 11 a.m.-12:15 p.m., Bldg. 37 Rooms 4041/4107, NCI, Bethesda
"Monoclonal antibody drug and target discovery in chronic lymphocytic leukemia“

 

Richard A. Morgan (NCI)
June 4, 2010 (Friday) 11 a.m.-12:15 p.m., Bldg. 37 Rooms 4041/4107, NCI, Bethesda
"Turning antibodies into T cell receptors“

 

Paul Winfield (NIAMS)
June 25, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Structural studies on the HIV-1 Rev protein”

 

Wei Jin Wu (FDA)
July 23, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"The roles of IGFBPs: a novel mechanism of action for trastuzumab-mediated cell growth inhibition”

 

Dimiter S Dimitrov (NCI)
August 27, 2010 (Friday) 10-11:15 a.m., Bldg. 549 Executive Board Room, NCI, Frederick
"Engineered antibody domains as candidate therapeutics”

 

Edward A Berger (NIAID)
September 24, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Masking and Unmasking HIV Neutralizing Epitopes: from Implications to Applications”  

 

Manuel Baca (MedImmune, Inc.)
October 22, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Beyond Antibodies: Challenges and Opportunities for Alternative Scaffold Protein Drugs”   

 

 
National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892.
  Department of Health and Human Services   USA.gov - Government made easy